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The efficacy of isolated limb perfusion (ILP) for ‘in- 
transit’ metastases from malignant melanoma and 
irresectable soft tissue sarcoma has been improved 
considerably by the addition of tumour necrosis factor 
(TNF) a. A rat sarcoma tumour model was, therefore, 
developed to evaluate the effects of TNF-a, melphalan and 
the combination of these drugs in the treatment of 
sarcoma. In BN rats bearing the non-immunogenic 
BN 175 sarcoma ILPs were performed with perfusate only, 
TNF-a, melphalan alone, or in combination when tumours 
~~~ ~ 
had grown to approximately 1.5 cm in diameter. All rats 
treated with sham perfusion or perfusion with 50 pg TNF- 
a showed progressive disease. After perfusion with 40 pg 
melphalan no change in tumour diameter was observed in 
any rats at 4 days. After a combined perfusion with 40 pg 
melphalan and 50 pg TNF-a complete remission was noted 
in 12 of 16 rats. This synergistic effect in vivo between 
relatively ineffective doses of TNF-a and melphalan was 
not observed in vitro. 
Tumour necrosis factor (TNF) a in combination with 
interferon 1’ and melphalan in isolated limb perfusion 
(ILP) results in a high complete remission rate in patients 
with ‘in-transit’ metastases from malignant melanoma’.*. 
Identical treatment has been applied to patients with 
irresectable soft tissue sarcoma of the limbs in an attempt 
to render the tumours resectable and thus avoid 
amputation or disarticulation. An 88 per cent overall 
response rate with a limb salvage rate of 87 per cent has 
been reported’. ILP was first described by Creech et ~ 1 . ~  
and provides high regional drug concentrations with 
minimal systemic toxicity. Response rates obtained with 
ILP with conventional cytostatic agents, such as 
melphalan and doxorubicin, have been disappointing in 
patients with soft tissue sarcomas’.‘. This prompted 
Litnard and co-workers’ to investigate the addition of 
high doses of TNF-sl in the treatment of irresectable 
sarcomas. 
During ILP, tumours may be exposed to extremely high 
levels of TNF-x, but the disappointing results from 
systemic administration of TNF-a in phase 1-11 trials7-” 
may be because toxicity in humans allows only for the 
administration of about 1120-1/50 of the dose required for 
antitumour effects in murine experimental tumour 
models1z. As ILP can achieve a 20-fold increase in 
concentration of the drugl3, this may be the best way of 
determining whether TNF-sl can be used effectively. 
TNF-x as a single agent has only been administered by 
ILP in a small number of patients in a feasibility study. In 
this study, therefore, the efficacy of TNF-x, melphalan 
and the combination thereof was investigated in a rat 
model of ILP. 
Materials and methods 
Animals 
Male inbred BN strain rats, weighing 250-300 g and obtained 
from Harlan-CPB (Austerlitz, The Netherlands), were used. The 
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rats were fed a standard laboratory diet (Hope Farms, Woerden, 
The Netherlands). They were housed under standard conditions 
of light and accommodation. The experimental protocols 
adhered to the rules outlined in the Dutch Animal 
Experimentation Act 1977 and the published Guidelines on the 
Protection of Experimental Animals by the Council of the 
European Community 1986. The protocol was approved by the 
committee on animal research of the Erasmus University, 
Rotterdam, The Netherlands. 
Tumour 
The spontaneous BN 175 sarcoma (transplantable to BN rats) 
was ~ s e d ‘ ~ , ~ ~  and implanted subcutaneously in the flank and 
passaged serially. BN 175 sarcoma is a rapidly growing and 
metastasizing tumour. As determined by the immunization 
challenge method of Prehn and Mainlh, the BN 175 sarcoma is 
non-immunogenic and can be maintained in tissue culture. 
Melphalan 
Melphalan (Alkeran, 50 mg per vial; Wellcome, Beckenham, 
UK) was diluted in 10 ml diluent solvent. Further dilutions were 
made in 0.9 per cent NaCl to give a volume of 0.2ml in the 
perfusion circuit. 
Tumour necrosis factor a 
Recombinant human TNF-a was provided by Boehringer 
(Ingelheim, Germany) with a specific activity of 5.8 X 10’ units/ 
mg as determined in the murine L-M cell assay”. Endotoxin 
levels were less than 1.25 endotoxin units (EU) per mg protein. 
Tumour model 
Fragments (3-5 mm) of the BN 175 sarcoma were implanted 
into the right hindlimb subcutaneously just above the ankle. 
Perfusion was performed at a tumour diameter of approximately 
15 mm at least 7 days after implantation. Subsequent tumour 
growth was recorded by calliper measurement. The mean of two 
perpendicular diameters was obtained. Tumour diameters were 
measured at least three times weekly. 
The classification of tumour response was: progressive disease 
(increase in turnour diameter more than 25 per cent within 
4 days; no change (tumour diameter equal to diameter during 
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perfusion (range -50 to  +25 per cent)); partial remission 
(decrease in tumour diameter of less than -50 per cent; 
complete remission (no tumour palpable). When complete 
remission was associated with skin necrosis at the tumour site 
this response was classified as CR,,. 
Isolated limb perfusion 
Modification of the perfusion technique originally described by 
Benckhuijsen et al.In was used. Briefly, animals were 
anaesthetized with Hypnorm (Janssen Pharmaceutica, Tilburg, 
The Netherlands) and 50 units heparin was injected 
intravenously. To keep the rat's hindleg at a constant 
temperature of 38-39"C, a warm water mattress was applied. 
The femoral artery and vein were cannulated with silastic tubing 
(0.30 mm inner diameter, 0.64 mm outer diameter; 0.64 mm 
inner diameter, 1.19 mm outer diameter respectively; Dow 
Corning, Michigan, USA). Collaterals were occluded by a groin 
tourniquet and isolation time commenced when the tourniquet 
was tightened. An oxygenation reservoir and a roller pump were 
included in the circuit. The perfusion commenced with 5 ml 
Haemaccel (Behring Pharma, Amsterdam, The Netherlands), 
and the haemoglobin content of the perfusate was 0.9 mmol/l. 
Melphalan and TNF-a were added as boluses to the oxygenation 
reservoir. A roller pump (Watson Marlow, Falmouth, UK; type 
505 U) recirculated the perfusate at a flow rate of 2.4 mlimin. A 
washout with 2 ml oxygenated Haemaccel was performed at the 
end of the perfusion. In the rat collateral circulation via the 
internal iliac artery t o  the leg is so extensive that it allows 
ligation of the femoral vessels without detrimental effects and, 
after ligation of the femoral artery, backflow from the femoral 
vein was seen in all rats immediately after release of the 
tourniquet. The partial pressure of oxygen (P,,<J was similar 
before and after ligation of the femoral vessels'". 
In vivo tumour response studies 
Experiments were performed in five groups of rats; group I ,  
sham perfusion (11 = 0 ) ;  group 2, melphalan perfusion with total 
doses of 40 pg ( n  = 4), 0.2 mg ( n  = 6) and I mg ( n  = 4); group 3, 
perfusion with 40pg melphalan ( n  = 5 ) :  group 4, perfusion with 
50 pg TNF-x (n = 9); group 5 ,  perfusion with 40pg melphalan 
and 5 0 p g  TNF-x ( n  = 16). (Previous studies have shown that 
perfusions with even IOOpg TNF-x have n o  antitumour 
effects'".) 
Histology 
For histopathological studies an additional 16 rats were used: 
four per group were sacrificed 24 h after treatment. Tumours 
were excised and fixed in 4 per cent formaldehyde solution and 
embedded in paraffin. Sections of the tumour were stained with 
haematoxylin and eosin. 
In vitro assessment of antitumour activiy 
BN 175 sarcoma grows as a monolayer in Dulbecco's modified 
Eagle's medium containing 5 per cent fetal calf serum and 
glutamic acid 0.3 mmolil (Gibco, Paisley, UK). The 
sulphorhodamine B protein stain assay was used according to the 
method of Skehan et al."'. Eight replicate experiments were 
performed. Tumour growth was calculated using the formula: 
tumour growth = (test wellicontrol) X 100 per cent. The drug 
concentration reducing the absorbance to 50 per cent of control 
(IC5,,) was determined from the growth curves. Sensitization 
ratios of combinations of melphalan with TNF-x were 
determined by dividing the IC,,, in the presence of the single 
agent by the IC,,, in the presence of the additional agent. 
Statistical analysis 
To compare tumour diameters in different animal groups the 
Mann-Whitney U test and Student's t test were used. 
Results 
Dose ranging for melphalan 
Perfusions were performed with 1 mg, 0.2 mg and 40 pg 
melphalan. Perfusions with 1 mg melphalan resulted in 
tumour regression consisting of two of four partial 
remissions and two of four complete remissions. 
Remission was characterized by a gradual disappearance 
Table 1 Antitumour effects of isolated limb perfusion in the 
BN 175 sarcoma model 
Perfusion with 
Perfusion Perfusion 50 pg TNF-a 
Sham with 50 pg with 40 pg and 40 pg 
perfusion TNF-r melphalan melphalan 
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Progressive disease 9 9 0 0 
No change 0 0 9 4 
Partial remission 0 0 0 0 
Complete remission 0 0 0 3 
Complete remission 0 0 0 9 
and skin necrosis 
Total 9 9 9 16 
TNF-x, tumour necrosis factor r 
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Fig. 1 Growth curves of hindlimb BN 175 sarcoma after sham 
perfusion (m; n = 9), 50 p g  tumour necrosis factor (TNF) z (0; 
n = 9), 40 pg melphalan (0; n = Y), and TNF-s( plus melphalan 
(0; n = 16). Values are mean(s.e.m.) of tumour diameters. At 
day 5 after perfusion: combined versus melphalan group, 
combined versus TNF-a group, and melphalan versus TNF-x 
group show significant differences (P  < 0,001, Mann-Whitney U 
test and Student's t test). No significant difference was apparent 
between the TNF-a and sham groups (f" 0.05, Mann-Whitney 
U test and Student's t test) 
of tumour without darkening of the skin. Atrophy of the 
musculature occurred. In only one rat was a long-lasting 
complete remission obtained (sacrificed at day 105). 
Perfusion with 0.2 mg melphalan resulted in no change for 
four of six tumours and two of six complete remissions 
without marked atrophic changes in the hindleg. Perfusion 
with 40 pg melphalan inhibited tumour growth for at least 
4 days in four of four rats (Table 1).  
Tumour response study 
Results are summarized in Table 1. Sham perfusion and 
perfusion with TNF-rx did not inhibit tumour growth and 
progressive disease was observed in all rats in both 
groups. After perfusion with 40 pg melphalan tumour 
growth was arrested in all five animals for at least 4 days. 
Complete tumour remission occurred after combined 
perfusion with 50pg TNF-z and 40pg melphalan in 12 of 
16 rats; nine of the complete remissions were classified as 
CR,,. Recurrences were noted in eight of 16 rats. Eight 
rats did not have recurrences, but these rats had to be 
killed as they developed skin necrosis at the tumour site. 
100 r 
Regrowth of tumour was usually seen about 11 days after 
perfusion (mean(s.d.) 10.9(2.8) days). In Fig. I ,  growth 
curves of all treatment groups are shown. 
Histology 
In non-perfused tumours and those harvested 24 h after 
sham and melphalan ILP oedema, dilated vessels and 
lymphocytes, scattered through the tumour, were found. 
Haemorrhagic and ischaemic necrosis were absent or 
limited to less than 5 per cent. In addition, rats treated 
with TNF-a and the combination of melphalan and TNF-a 
demonstrated haemorrhagic necrosis in the central part of 
the tumour. In rats treated with TNF-a and melphalan 
haemorrhagic necrosis was much more extensive than in 
rats receiving ILP with TNF-a alone. In two rats 
margination of polymorphonuclear cells in the tumour 
vessels with increased influx into the tumour was 
observed. 
80 I \  
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Fig. 2 Doseiresponse curve of BN 175 sarcoma to tumour 
necrosis factor (TNF) ct determined in the sulphorhodamine B 
assay 
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Melphalan (pg/rnl) 
Fig. 3 Doseiresponse curve of BN 175 sarcoma to melphalan in 
the absence of tumour necrosis factor (TNF) CI (W), in the 
presence of 0.1 pLg/ml TNF-x (0), and 1.0 pLg/ml TNF-a (O), 
determined in the sulphorhodamine B assay 
In vitro cytotoxicity assay 
The in vitro dose/response curve of BN 175 sarcoma cells 
to TNF-a is depicted in Fig. 2. In Fig. 3 the dose/response 
curves with melphalan alone or combined with 0.1 and 
1.0pdml TNF-a are depicted. The IC,,,s were equivalent 
for 0 and 0.1 pdml  TNF-a, but attenuated in the presence 
of 1.0 p d m l  TNF-rx. The mean(s.d.) sensitization ratio in 
the presence of 1.0pdml TNF-rx was 2.9(0.5) calculated 
from three different experiments. As 1.0 pdml  TNF-a 
alone can reduce tumour growth to 55 per cent, the 
enhanced cytotoxicity is probably due to additive effects. 
These experiments have shown that TNF-a is only 
effective when administered in combination with 
melphalan. Isolated limb perfusion with perfusate alone 
or 50pg TNF-a alone had no impact on tumour growth 
and 40 pg  melphalan only temporarily inhibited tumour 
growth. In the groups perfused with the combination of 
both complete remission occurred in 12 of 16 rats. 
Histologically, haemorrhagic necrosis was observed after 
ILP with TNF-a alone but this was much more extensive 
with the combined treatment. 
Interaction of the two agents on direct tumour 
cytotoxicity could be one explanation for the in vivo 
synergism observed. I n  vitro studies demonstrated no 
synergy, but an additive effect at best. All observations 
therefore indicate that the in vivo antitumour effects are 
mediated by indirect mechanisms such as effects on 
the tumour-associated vasculature (TAV); increased 
penetration of the cytostatic agent by these effects on 
TAV; and the immune system. 
Disappearance of the tumour within 2-3 days together 
with the histological ObSeNatiOtI of haemorrhagic necrosis 
are typical of TNF-a treatment based on the vascular 
effects reported in many experimental ~ t u d i e s ~ ' - ~ ~ .  
Increased endothelial permeability, erythrostasis and 
thrombocyte aggregation, followed by vascular occlusion 
and haemorrhagic necrosis have been described in 
tumours treated with ILP and TNF-a in patientsz4. 
Moreover, preferential occlusion of all the TAV has been 
demonstrated angiographically in patients after ILP2'. 
Combination of TNF-rx with mslphalan resulted in 
remission, which was associated with extensive 
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haemorrhagic necrosis of the tumour within 24 h of ILP. 
This suggests a potentiating role of melphalan on the 
effects of TNF-a on the TAV. For  extensive haemorrhagic 
necrosis t o  occur, another detrimental agent in addition t o  
TNF-a was apparently necessary. As with the alkylating 
agent cyclophosphamide, melphalan may well induce 
damage t o  endothelial cells2h. 
Better penetration of the therapeutic agents may result 
from increased permeability of T A V  induced by TNF-a. 
T h e  synergism of specific immune therapy and 
cyclophosphamide in a guinea-pig metastasis model was 
also found to b e  associated with vascular leakage within 
t u m ~ l ~ r ~ ~ ~ .  In recent studies the accessibility of 
monoclonal antibodies was increased after the 
administration of TNF-a2*. Based on these reports, 
melphalan delivery t o  the  tumour may be enhanced by 
For  sequential biopsies in patients, changes in T A V  are  
associated with leucocyte infiltration in the turnour*’. By 
contrast, in the  present rat model increased poly- 
morphonuclear cell margination and influx was not 
uniformly present in the  areas of haemorrhagic necrosis. 
In previous studies in mice polymorphonuclear cells and 
macrophages have been implicated in the induction of 
haemorrhagic necrosis by TNF-a3”.”. As distinct from 
their role in early TNF-a effects such as haemorrhagic 
necrosis, inflammatory cells a re  probably of crucial 
importance in tumour regression in later phases32. 
However, this has only been shown t o  be  the case in 
immunogenic and not in non-immunogenic tumourslZ. As 
a non-immunogenic tumour was used, it is likely that a 
second step immune reaction lollowing haemorrhagic 
necrosis may not b e  relevant in this model. In non- 
immunogenic tumours, a viable rim of tumour is 
suggested to replace the central haemorrhagic necrosis in 
the tumour”. This explains the lack of tumour regression, 
despite haemorrhagic necrosis, found after ILP with TNF- 
CI alone in this model. 
In conclusion, these experiments have revealed 
synergism between TNF-a and melphalan with a 75 per 
cent complete response rate. The model appears, 
therefore, t o  be  clinically relevant. The  synergy observed 
is mainly mediated by indirect antitumour mechanisms 
such as the destruction of TAV and consequently a n  
enhanced efficacy of melphalan. Further elucidation of 
the mechanisms involved will be necessary t o  allow 
development of treatment programmes and to  extend 
isolated perfusion with TNF-a to  the  treatment of other  
tumours such as those in the  liver and 
TNF-a. 
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